796875-26-8Relevant articles and documents
Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists
Kim, Jong Yup,Seo, Hee Jeong,Lee, Sung-Han,Jung, Myung Eun,Ahn, Kwangwoo,Kim, Jeongmin,Lee, Jinhwa
body text, p. 142 - 145 (2009/05/30)
Since the CB1 receptor antagonist SR141716 (rimonabant) was reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target in the treatment of obesity. Several series of derivatives based on diarylimidazolyl oxadiazole an
Bioisosteric replacements of the pyrazole moiety of rimonabant: Synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists
Lange, Jos H. M.,Van Stuivenberg, Herman H.,Coolen, Hein K. A. C.,Adolfs, Tiny J. P.,McCreary, Andrew C.,Keizer, Hiskias G.,Wals, Henri C.,Veerman, Willem,Borst, Alice J. M.,De Looff, Wouter,Verveer, Peter C.,Kruse, Chris G.
, p. 1823 - 1838 (2007/10/03)
Series of thiazoles, triazoles, and imidazoles were designed as bioisosteres, based on the 1,5-diarylpyrazole motif that is present in the potent CB1 receptor antagonist rimonabant (SR141716A, 1). A number of target compounds was synthesized an
